ES2138565B1 - Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. - Google Patents
Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.Info
- Publication number
- ES2138565B1 ES2138565B1 ES009801003A ES9801003A ES2138565B1 ES 2138565 B1 ES2138565 B1 ES 2138565B1 ES 009801003 A ES009801003 A ES 009801003A ES 9801003 A ES9801003 A ES 9801003A ES 2138565 B1 ES2138565 B1 ES 2138565B1
- Authority
- ES
- Spain
- Prior art keywords
- livers
- treatment
- viral
- subtype
- ifna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003612 virological effect Effects 0.000 title abstract 3
- 102000006992 Interferon-alpha Human genes 0.000 title 1
- 108010047761 Interferon-alpha Proteins 0.000 title 1
- 210000004185 liver Anatomy 0.000 abstract 5
- 102000014150 Interferons Human genes 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
- 208000019423 liver disease Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
Abstract
Uso del interferon alfa-5 en el tratamiento de las hepatopatías virales. La invención describe la síntesis disminuida de IFNa-5 en hígados de pacientes con hepatitis C, frente a hígados de controles sanos. El subtipo de IFN expresado en dichos hígados sanos, correspondió únicamente al subtipo alfa-5, frente a los diferentes subtipos expresados en hígados enfermos. En SEQ ID NO:1 se muestra la secuencia parcial de cADN correspondiente a IFNa 5. Estas diferencias significativas entre los patrones de expresión de unos hígados y otros ponen de manifiesto la importancia del uso de este subtipo de interferon en la fabricación de composiciones útiles en el tratamiento de hepatopatías de origen viral. En la invención se describe pormenorizadamente esta utilización bajo diferentes formas y procedimientos, incluyendo aquellos que utilizan la producción de proteínas recombinantes, a partir de secuencias tipo SEQ ID NO:1.
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009801003A ES2138565B1 (es) | 1998-05-13 | 1998-05-13 | Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. |
AU37111/99A AU753463B2 (en) | 1998-05-13 | 1999-05-13 | Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
AT99919282T ATE214941T1 (de) | 1998-05-13 | 1999-05-13 | Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien |
CA2335645A CA2335645C (en) | 1998-05-13 | 1999-05-13 | Use of interferon alpha 5 in the treatment of viral liver diseases |
CNB998078662A CN1173738C (zh) | 1998-05-13 | 1999-05-13 | 干扰素α5在制备治疗病毒性肝脏疾病的组合物中的应用 |
ES99919282T ES2174604T3 (es) | 1998-05-13 | 1999-05-13 | Utilizacion de interferon alfa 5 en el tratamiento de las hepatopatias de origen viral. |
PCT/ES1999/000134 WO1999058143A1 (es) | 1998-05-13 | 1999-05-13 | Uso del interferon alfa 5 en el tratamiento de las hepatopatias virales |
BR9911774-6A BR9911774A (pt) | 1998-05-13 | 1999-05-13 | Uso de interferon alfa 5 no tratamento das hepatopatias virais |
SI9930043T SI1077068T1 (en) | 1998-05-13 | 1999-05-13 | Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
DE69901099T DE69901099T4 (de) | 1998-05-13 | 1999-05-13 | Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien |
RU2000131172/14A RU2209079C2 (ru) | 1998-05-13 | 1999-05-13 | Применение интерферона-альфа 5 в лечении вирусных заболеваний печени |
JP2000547994A JP2002514606A (ja) | 1998-05-13 | 1999-05-13 | ウィルス性肝疾患の治療へのインターフェロンα5の使用 |
EP99919282A EP1077068B9 (en) | 1998-05-13 | 1999-05-13 | Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
DE69901099A DE69901099D1 (de) | 1998-05-13 | 1999-05-13 | Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien |
PT99919282T PT1077068E (pt) | 1998-05-13 | 1999-05-13 | Utilizacao do interferao alfa 5 no tratamento de hepatopatias virais |
SE99919282T SE1077068T5 (sv) | 1998-05-13 | 1999-05-13 | Anvaendning av interferon-alfa-5 vid behandling av virus-hepatopatier |
DK99919282T DK1077068T5 (da) | 1998-05-13 | 1999-05-13 | Anvendelse af interferon alfa 5 i behandlingen af virale hepatopatier |
US09/674,445 US6995133B1 (en) | 1998-05-13 | 1999-05-13 | Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
US11/212,126 US7501392B2 (en) | 1998-05-13 | 2005-08-25 | Method of treatment of viral hepatitis C with interferon alpha 5 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009801003A ES2138565B1 (es) | 1998-05-13 | 1998-05-13 | Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2138565A1 ES2138565A1 (es) | 2000-01-01 |
ES2138565B1 true ES2138565B1 (es) | 2000-08-16 |
Family
ID=8303773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES009801003A Expired - Lifetime ES2138565B1 (es) | 1998-05-13 | 1998-05-13 | Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. |
ES99919282T Expired - Lifetime ES2174604T3 (es) | 1998-05-13 | 1999-05-13 | Utilizacion de interferon alfa 5 en el tratamiento de las hepatopatias de origen viral. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99919282T Expired - Lifetime ES2174604T3 (es) | 1998-05-13 | 1999-05-13 | Utilizacion de interferon alfa 5 en el tratamiento de las hepatopatias de origen viral. |
Country Status (15)
Country | Link |
---|---|
US (2) | US6995133B1 (es) |
EP (1) | EP1077068B9 (es) |
JP (1) | JP2002514606A (es) |
CN (1) | CN1173738C (es) |
AT (1) | ATE214941T1 (es) |
AU (1) | AU753463B2 (es) |
BR (1) | BR9911774A (es) |
CA (1) | CA2335645C (es) |
DE (2) | DE69901099T4 (es) |
DK (1) | DK1077068T5 (es) |
ES (2) | ES2138565B1 (es) |
PT (1) | PT1077068E (es) |
RU (1) | RU2209079C2 (es) |
SE (1) | SE1077068T5 (es) |
WO (1) | WO1999058143A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110179530A1 (en) * | 2001-01-23 | 2011-07-21 | University Of Central Florida Research Foundation, Inc. | Pharmaceutical Proteins, Human Therapeutics, Human Serum Albumin Insulin, Native Cholera Toxin B Subunit on Transgenic Plastids |
FR2824333B1 (fr) * | 2001-05-03 | 2003-08-08 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'ifn alpha 5 |
ES2303492A1 (es) * | 2004-08-18 | 2008-08-01 | Instituto Cientifico Y Tecnologico De Navarra S.A. | Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden. |
WO2006032711A1 (es) * | 2004-08-18 | 2006-03-30 | Instituto Científico Y Tecnológico De Navarra S.A. | Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden |
MX2012008893A (es) * | 2010-02-01 | 2013-02-27 | Digna Biotech Sl | Procedimiento para la produccion de interferon alfa 5. |
BR112013032188A2 (pt) | 2011-06-23 | 2016-12-20 | Digna Biotech Sl | composição, produto e método para tratar pacientes com hepatite c crônica |
LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4973479A (en) * | 1982-01-15 | 1990-11-27 | Cetus Corporation | Interferon-α61 |
ATE193724T1 (de) * | 1991-03-12 | 2000-06-15 | Biogen Inc | Cd2 bindender bereich für das lymphocyten- funktion assoziierte antigen-3 |
DK0741577T3 (da) * | 1994-03-07 | 2003-02-17 | Imperial College | Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
-
1998
- 1998-05-13 ES ES009801003A patent/ES2138565B1/es not_active Expired - Lifetime
-
1999
- 1999-05-13 AU AU37111/99A patent/AU753463B2/en not_active Ceased
- 1999-05-13 DE DE69901099T patent/DE69901099T4/de not_active Expired - Lifetime
- 1999-05-13 EP EP99919282A patent/EP1077068B9/en not_active Expired - Lifetime
- 1999-05-13 DE DE69901099A patent/DE69901099D1/de not_active Expired - Lifetime
- 1999-05-13 PT PT99919282T patent/PT1077068E/pt unknown
- 1999-05-13 CN CNB998078662A patent/CN1173738C/zh not_active Expired - Fee Related
- 1999-05-13 RU RU2000131172/14A patent/RU2209079C2/ru not_active IP Right Cessation
- 1999-05-13 US US09/674,445 patent/US6995133B1/en not_active Expired - Fee Related
- 1999-05-13 JP JP2000547994A patent/JP2002514606A/ja active Pending
- 1999-05-13 BR BR9911774-6A patent/BR9911774A/pt not_active Application Discontinuation
- 1999-05-13 AT AT99919282T patent/ATE214941T1/de active
- 1999-05-13 DK DK99919282T patent/DK1077068T5/da active
- 1999-05-13 CA CA2335645A patent/CA2335645C/en not_active Expired - Fee Related
- 1999-05-13 SE SE99919282T patent/SE1077068T5/xx unknown
- 1999-05-13 WO PCT/ES1999/000134 patent/WO1999058143A1/es active IP Right Grant
- 1999-05-13 ES ES99919282T patent/ES2174604T3/es not_active Expired - Lifetime
-
2005
- 2005-08-25 US US11/212,126 patent/US7501392B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PT1077068E (pt) | 2002-07-31 |
EP1077068B1 (en) | 2002-03-27 |
AU753463B2 (en) | 2002-10-17 |
CA2335645C (en) | 2011-01-04 |
EP1077068B9 (en) | 2002-10-02 |
US20060188477A1 (en) | 2006-08-24 |
SE1077068T3 (sv) | 2002-07-02 |
ATE214941T1 (de) | 2002-04-15 |
ES2174604T3 (es) | 2002-11-01 |
CN1173738C (zh) | 2004-11-03 |
CN1307482A (zh) | 2001-08-08 |
DE69901099D1 (de) | 2002-05-02 |
EP1077068A1 (en) | 2001-02-21 |
RU2209079C2 (ru) | 2003-07-27 |
US6995133B1 (en) | 2006-02-07 |
JP2002514606A (ja) | 2002-05-21 |
BR9911774A (pt) | 2001-02-06 |
DK1077068T3 (da) | 2002-07-22 |
ES2138565A1 (es) | 2000-01-01 |
DE69901099T2 (de) | 2002-11-07 |
WO1999058143A9 (es) | 2002-08-22 |
US7501392B2 (en) | 2009-03-10 |
DE69901099T4 (de) | 2003-03-13 |
DK1077068T5 (da) | 2002-10-14 |
SE1077068T5 (sv) | 2003-03-04 |
CA2335645A1 (en) | 1999-11-18 |
WO1999058143A1 (es) | 1999-11-18 |
AU3711199A (en) | 1999-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9912448A (pt) | Composto, composição farmacêutica, e, processos de indução de biossìntese de citoquina em um mamìfero, de tratamento de uma doença virótica em um mamìfero, e de tratamento de uma doença neoplásica em um mamìfero | |
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
ATE442378T1 (de) | Substituierte wt1-peptide | |
ES2186660T3 (es) | Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica. | |
BR0009964A (pt) | Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial | |
ATE209216T1 (de) | Cyclosporin-derivate mit anti-hiv-wirkung | |
DE10299044I1 (de) | n-Terminal chemisch modifizierte Protein-Zusammensetzungen und Methoden | |
DE69839812D1 (de) | Analoge des menschlichen interferon-alpha mit niedriger toxizität | |
CO5241328A1 (es) | Constructo de adn para la obtencion recombinante de saratina | |
ES2138565B1 (es) | Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. | |
ATE256736T1 (de) | Ein nicht-mitogener kompetitiver hgf-antagonist | |
ECSP066352A (es) | Preparación de péptidos de somatostatina | |
DK1501936T3 (da) | Familie af cytokin-proteiner | |
UY27827A1 (es) | Composiciones y su uso terapeutico | |
PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
DE60239670D1 (de) | Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis | |
BR0311696A (pt) | Tratamento de hepatite c na população asiática com interferon-beta subcutâneo | |
AR038900A1 (es) | Moleculas similares al interferon beta para el tratamiento del derrame cerebral | |
ATE371737T1 (de) | Proteaseresistente flint-analoge | |
AR026068A1 (es) | Peptidos modificados y peptidomimeticos para el uso en inmunoterapia. | |
ATE333274T1 (de) | Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii | |
BRPI0406985A (pt) | Terapia de combinação de hcv | |
ES2160927T3 (es) | Composiciones farmaceuticas que comprenden interferon alfa humano natural. | |
IT1312060B1 (it) | Uso dell'acido alfa lipoico nel trattamento antimetastatico. | |
ES2170797T3 (es) | Procedimiento de amplificacion enzimatica (in vitro) de un fragmento de adn con la ayuda de iniciadores en escalera. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20000101 Kind code of ref document: A1 Effective date: 20000101 |